Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 7/20 | 0.54 |
| ▸ | PPARG | P37231 | 11/20 | 0.47 |
| ▸ | MPC2 | O95563 | 2/20 | 0.47 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
| ▸ | RARG | P13631 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6185615 | 0.94 | FFAR1 (0.53) | FFAR1PPARGMPC2CYP2C8CYP2C9 | |
| SCHEMBL5394455 | 0.92 | FFAR1 (0.51) | FFAR1PPARGMPC2CYP2C8CYP2C9 | |
| SCHEMBL5390364 | 0.92 | FFAR1 (0.51) | FFAR1PPARGMPC2CYP2C8CYP2C9 | |
| SCHEMBL6188185 | 0.91 | MAPT (0.51) | FFAR1PPARGMPC2CYP2C8CYP2C9 | |
| SCHEMBL5388747 | 0.91 | FFAR1 (0.66) | FFAR1PPARGMPC2CYP2C8CYP2C9 | |
| SCHEMBL5394084 | 0.90 | FFAR1 (0.52) | FFAR1PPARGMPC2CYP2C8CYP2C9 | |
| SCHEMBL6184382 | 0.89 | FFAR1 (0.48) | FFAR1PPARGMPC2CYP2C8CYP2C9 | |
| SCHEMBL5383043 | 0.89 | FFAR1 (0.46) | FFAR1PPARGMPC2CYP2C8CYP2C9 | |
| SCHEMBL6182666 | 0.89 | FFAR1 (0.52) | FFAR1PPARGMPC2CYP2C8CYP2C9 | |
| SCHEMBL6184533 | 0.88 | FFAR1 (0.57) | FFAR1PPARGMPC2CYP2C8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6927228-B2 | Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-08-09 | — | — | US | claimed |
| EP-1309575-B1 | BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS | GALDERMA RES & DEV (FR) | 2005-06-08 | — | — | EP | claimed |
| US-20040039038-A1 | Biaromatic compound activators of PPARy-type receptors | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-26 | — | — | US | claimed |
| EP-1309575-A1 | BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS | Galderma Research & Development (FR) | 2003-05-14 | — | — | EP | claimed |
| WO-2002012210-A9 | BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS | GALDERMA RES & DEV (FR) | 2002-04-18 | — | — | WO | claimed |
| WO-2002012210-A1 | BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2002-02-14 | — | — | WO | claimed |
| US-6927228-B2 | Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-08-09 | — | — | US | disclosed |
| EP-1309575-B1 | BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS | GALDERMA RES & DEV (FR) | 2005-06-08 | — | — | EP | disclosed |
| US-20040039038-A1 | Biaromatic compound activators of PPARy-type receptors | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-26 | — | — | US | disclosed |
| EP-1309575-A1 | BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS | Galderma Research & Development (FR) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002012210-A9 | BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS | GALDERMA RES & DEV (FR) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002012210-A1 | BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039038-A1 | Biaromatic compound activators of PPARy-type receptors | PPARG, PPARA, PPARD | FFAR1 6/4885PPARG 1/4885MPC2 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.